Calyx Reports Change of Auditor

Calyx Reports Change of Auditor
  
 

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 25, 2014) - Pursuant to section 4.11 of National Instrument 51-102, Calyx Bio-Ventures Inc. (TSX-VENTURE:CYX) ("Calyx" or the "Company") announces it has changed auditors and has filed a reporting package at www.sedar.com with respect to the change of auditor.

The reporting package contains the following documents:

• an executed Notice of Change of Auditor;
• a letter to the former auditor, Ernst & Young, LLP ("E&Y);
• a letter from the successor auditor Dale Matheson Carr-Hilton Labonte LLP;
• a letter from the former auditor, E&Y; and
• a letter confirming that the above-listed documents have been reviewed by the Board of Directors of the Company.

About Calyx

Calyx Bio-Ventures Inc. (TSX-VENTURE:CYX) is an agricultural technology company which is developing early stage agriculture ventures. Calyx brings its depth of experience, capital and other capacity including its proprietary intellectual property to enhance plant yields. In addition to Calyx's position as a shareholder of Agrisoma Biosciences Inc., a company which is producing a non-food energy feedstock crop for bioenergy, Calyx is pursuing agri-pharmaceutical opportunities in the MMPR (Marijuana for Medical Purposes Regulations) and the agri-tech space. For further information about Calyx, please visit www.calyxbio.com.

Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, or performance that may constitute "forward-looking statements" or "forward-looking information" under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx's control.

Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect.

Although Calyx believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and described in the forward-looking statements or information.

The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Calyx Bio-Ventures Inc.Don KonantzPresident & [e-mail] Bio-Ventures Inc.Investor Relations:Keir [e-mail]